Right selection of oral anticoagulation for stroke prevention in atrial fibrillation

Atrial fibrillation (AF) is considered as one of the most common cardiac arrhythmias worldwide and always associated with a significantly increased risk stroke thromboembolism. VKAs (Warfarin & Acenocoumarol) are highly effective in reducing patients AF, but bleeding issues disutility sparked development direct oral anticoagulants (DOACs) or NOACs (Novel anticoagulants). These drugs, offer convenience once twice daily dosing without need for laboratory monitoring coagulation activity (PT/ INR) routine dose adjustment. Various clinical trials proved their non-inferiority to warfarin (VKA) systemic embolism, each was markedly lower rates ICH than well-adjusted warfarin. Yet there no head-to-head comparative efficacy safety NOACs. In this review we try provide patient centric approach assist Indian physicians selecting right OAC therapy SPAF respect best possible evidence recommendations available worldwide.